Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

>The UK MHRA has approved toripalimab for the treatment of NPC and ESCC

Junshi Biosciences Announces Ongericimab’s NDA Approval in China

>The NMPA approved the NDA for ongericimab (PCSK9) for the treatment of primary hypercholesterolemia and mixed dyslipidemia (in combination with statins)

Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab

>The European Commission has approved toripalimab for the 1st-line treatment of advanced NPC and ESCC

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

>The NMPA has approved the supplemental new drug application for toripalimab in combination with axitinib for the first-line treatment of patients with medium to high risk unresectable or metastatic renal cell carcinoma